Filing Details
- Accession Number:
- 0001209191-13-024590
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-05-07 16:30:10
- Reporting Period:
- 2013-05-03
- Filing Date:
- 2013-05-07
- Accepted Time:
- 2013-05-07 16:30:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1190290 | Elaine Ullian | C/O Vertex Pharmaceuticals Incorporated 130 Waverly St. Cambridge MA 02139 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-05-03 | 20,000 | $29.84 | 25,265 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2013-05-03 | 20,000 | $29.89 | 45,265 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-05-03 | 40,000 | $77.99 | 5,265 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2013-05-03 | 20,000 | $0.00 | 20,000 | $29.84 |
Common Stock | Stock Option (right to buy) | Disposition | 2013-05-03 | 20,000 | $0.00 | 20,000 | $29.89 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2017-05-31 | No | 4 | M | Direct | |
0 | 2019-05-31 | No | 4 | M | Direct |
Footnotes
- Open market sales reported on this line occurred at a weighted average price of $77.99 (range $77.95 to $78.15).
- Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Fully vested.